Day & Ennis LLC reduced its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 0.7% during the first quarter, Holdings Channel reports. The firm owned 1,956 shares of the medical research company’s stock after selling 14 shares during the period. Day & Ennis LLC’s holdings in Thermo Fisher Scientific were worth $300,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. BB&T Securities LLC increased its stake in Thermo Fisher Scientific by 4.4% in the first quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock worth $13,798,000 after buying an additional 3,819 shares during the period. Toronto Dominion Bank increased its stake in Thermo Fisher Scientific by 53.5% in the first quarter. Toronto Dominion Bank now owns 107,099 shares of the medical research company’s stock worth $16,450,000 after buying an additional 37,307 shares during the period. Tompkins Financial Corp increased its stake in Thermo Fisher Scientific by 0.8% in the first quarter. Tompkins Financial Corp now owns 5,183 shares of the medical research company’s stock worth $733,000 after buying an additional 40 shares during the period. Huntington National Bank increased its stake in Thermo Fisher Scientific by 6.9% in the first quarter. Huntington National Bank now owns 186,907 shares of the medical research company’s stock worth $28,708,000 after buying an additional 12,025 shares during the period. Finally, Advisors Asset Management Inc. increased its stake in Thermo Fisher Scientific by 1.1% in the first quarter. Advisors Asset Management Inc. now owns 66,308 shares of the medical research company’s stock worth $10,185,000 after buying an additional 735 shares during the period. 87.15% of the stock is owned by institutional investors.

Shares of Thermo Fisher Scientific Inc (TMO) traded up 0.87% on Friday, hitting $173.23. The stock had a trading volume of 2,202,642 shares. The company’s 50-day moving average price is $176.78 and its 200 day moving average price is $165.46. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $182.87. The firm has a market cap of $67.58 billion, a P/E ratio of 30.18 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.03 earnings per share. On average, equities research analysts forecast that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be issued a $0.15 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.35%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.45%.

ILLEGAL ACTIVITY WARNING: “Thermo Fisher Scientific Inc (TMO) Position Cut by Day & Ennis LLC” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/12/thermo-fisher-scientific-inc-tmo-position-cut-by-day-ennis-llc.html.

TMO has been the subject of a number of recent analyst reports. Cantor Fitzgerald initiated coverage on Thermo Fisher Scientific in a report on Thursday, May 18th. They issued an “overweight” rating and a $194.00 target price for the company. Barclays PLC set a $175.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Wednesday, April 26th. Cowen and Company reissued an “outperform” rating and issued a $185.00 target price (up previously from $175.00) on shares of Thermo Fisher Scientific in a report on Saturday, April 29th. Citigroup Inc. reissued a “buy” rating and issued a $201.00 target price (up previously from $182.00) on shares of Thermo Fisher Scientific in a report on Monday, July 10th. Finally, BidaskClub raised Thermo Fisher Scientific from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. One investment analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $188.56.

In other news, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $176.26, for a total value of $440,650.00. Following the completion of the sale, the chief financial officer now owns 37,790 shares in the company, valued at $6,660,865.40. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Daniel P. Shine sold 4,688 shares of the company’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $171.88, for a total value of $805,773.44. Following the completion of the sale, the insider now owns 29,200 shares of the company’s stock, valued at approximately $5,018,896. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,188 shares of company stock valued at $4,702,223. Insiders own 0.49% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.